The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

Lotte M. Knapen*, Rutger H. T. Koornstra, Johanna H. M. Driessen, Bas van Vlijmen, Sander Croes, Stein Schalkwijk, Angela Colbers, Winald R. Gerritsen, David M. Burger, Frank de Vries, Nielka P. van Erp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)363-370
Number of pages8
JournalTargeted Oncology
Volume13
Issue number3
DOIs
Publication statusPublished - Jun 2018

Keywords

  • TUMOR RESPONSE
  • OPEN-LABEL
  • PHARMACOKINETICS
  • TOLERANCE
  • SURVIVAL
  • EFFICACY
  • SAFETY

Cite this